IRCT20140818018842N22 IRCT 2022-01-12 Tehran University of Medical Sciences Evaluation of the COVID-19 vaccine efficacy following allogeneic stem cell transplantation ESVIRHSCT Evaluation of safety and immunogenicity of the SARS-CoV-2 recombinant spike RBD protein vaccine in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation; A phase 2 clinical trial 2022-01-15 anticipated 40 Complete https://irct.ir/trial/61044 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Prevention. 2 Allogeneic stem cells transplantation. All consecutive adult patients who are candidates for Allo-HSCT at HORCSCT are recruited. They sign an informed consent to administer the Pastocovac vaccine and take blood samples. All patients who meet the inclusion criteria are enrolled to study from 3 to 12 months after Allo-HSCT and will be vaccinated with the first two doses of Pastucovac at a 4-week (±7 days) interval and a third additional dose with an 8-week (±7 days) interval from the second dose. Peripheral blood samples are collected before conditioning and before the first dose of vaccine to test particular lymphocyte subpopulations and SARS-CoV-2 IgG titers. The blood samples are also collected three weeks (± one week) after each dose of vaccine to assess serologic response by SARS-CoV-2 IgG titer.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information